Key amino acid residues in the melanocortin-4 receptor for nonpeptide THIQ specific binding and signaling

Regulatory Peptides

Volumn 155, Issue 1-3, 2009, Pages 46-54

  Yang, Yingkui ^a   Cai, Minying ^b   Chen, Min ^c   Qu, Hongchang ^b   McPherson, David ^d   Hruby, Victor ^b   Harmon, Carroll M ^b  

^a Kentucky   (United States)

^b University of Arizona   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

GPCR; MC4R; MSH; Nonpeptide; Obesity

Indexed keywords

AMINO ACID; CHIMERIC PROTEIN; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN RECEPTOR AGONIST; N 1 4 TETRAHYDROISOQUINOLINIUM 3 YLCARBONYL 1 (4 CHLOROBENZYL) 2 4 CYCLOHEXYL 4 (1H 1,2,4 TRIAZOL 1 YLMETHYL)PIPERIDIN 1 YL 2 OXOETHYLAMINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; CELL LINE; FLOW CYTOMETRY; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; RECEPTOR, MELANOCORTIN, TYPE 4; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; TETRAHYDROISOQUINOLINES; TRIAZOLES;

EID: 67349113399     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2009.03.006     Document Type: Article

References (62)

1. Hotu S., Carter B., Watson P., Cutfield W., and Cundy T. Increasing prevalence of type 2 diabetes in adolescents. J Paediatr Child Health 40 (2004) 201-204
2. Bhargava S.K., Sachdev H.S., Fall C.H., Osmond C., Lakshmy R., Barker D.J., Biswas S.K., Ramji S., Prabhakaran D., and Reddy K.S. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med 350 (2004) 865-875
3. Nammi S., Koka S., Chinnala K.M., and Boini K.M. Obesity: an overview on its current perspectives and treatment options. Nutr J 3 (2004) 3
4. Bray G. Drug treatment of obesity: don't throw the baby out with the bath water. Am J Clin Nutr 67 (1998) 1-2
5. Bray G.A. Obesity: a time bomb to be defused. Lancet 352 (1998) 160-161
6. Bray G.A., and Tartaglia L.A. Medicinal strategies in the treatment of obesity. Nature 404 (2000) 672-677
7. Boston B.A. Pro-opiomelanocortin and weight regulation: from mice to men. J Pediatr Endocrinol Metab 14 Suppl 6 (2001) 1409-1416
8. Boutin P., and Froguel P. Genetics of human obesity. Best Pract Res Clin Endocrinol Metab 15 (2001) 391-404
9. Hu Y., Bloomquist B.T., Cornfield L.J., DeCarr L.B., Flores-Riveros J.R., Friedman L., Jiang P., Lewis-Higgins L., Sadlowski Y., Schaefer J., Velazquez N., and McCaleb M.L. Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J Biol Chem 271 (1996) 26315-26319
10. Bultman S.J., Michaud E.J., and Woychik R.P. Molecular characterization of the mouse agouti locus. Cell 71 (1992) 1195-1204
11. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
12. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., Williams S.C., Richarson J.A., Kozlowski G.P., Wilson S., Arch J.R., Buckingham R.E., Haynes A.C., Carr S.A., Annan R.S., McNulty D.E., Liu W.S., Terrett J.A., Elshourbagy N.A., Bergsma D.J., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92 (1998) [1 page following 696]
13. Shimada M., Tritos N.A., Lowell B.B., Flier J.S., and Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 396 (1998) 670-674
14. Baltatzi M., Hatzitolios A., Tziomalos K., Iliadis F., and Zamboulis C. Neuropeptide Y and alpha-melanocyte-stimulating hormone: interaction in obesity and possible role in the development of hypertension. Int J Clin Pract 62 (2008) 1432-1440
15. Kaelin C.B., Candille S.I., Yu B., Jackson P., Thompson D.A., Nix M.A., Binkley J., Millhauser G.L., and Barsh G.S. New ligands for melanocortin receptors. Int J Obes (Lond) 32 Suppl 7 (2008) S19-S27
16. Millington G.W. The role of proopiomelanocortin (POMC) neurones in feeding behaviour. Nutr Metab (Lond) 4 (2007) 18
17. Nogueiras R., Wiedmer P., Perez-Tilve D., Veyrat-Durebex C., Keogh J.M., Sutton G.M., Pfluger P.T., Castaneda T.R., Neschen S., Hofmann S.M., Howles P.N., Morgan D.A., Benoit S.C., Szanto I., Schrott B., Schurmann A., Joost H.G., Hammond C., Hui D.Y., Woods S.C., et al. The central melanocortin system directly controls peripheral lipid metabolism. J Clin Invest 117 (2007) 3475-3488
18. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., Gu W., Kesterson R.A., Boston B.A., Cone R.D., Smith F.J., Campfield L.A., Burn P., and Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88 (1997) 131-141
19. Fan W., Boston B.A., Kesterson R.A., Hruby V.J., and Cone R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385 (1997) 165-168
20. Giraudo S.Q., Billington C.J., and Levine A.S. Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands. Brain Res 809 (1998) 302-306
21. Cone R.D. The central melanocortin system and energy homeostasis. Trends Endocrinol Metab 10 (1999) 211-216
22. Fisher S.L., Yagaloff K.A., and Burn P. Melanocortin-4 receptor: a novel signalling pathway involved in body weight regulation. Int J Obes Relat Metab Disord 23 Suppl 1 (1999) 54-58
23. Emmerson P.J., Fisher M.J., Yan L.Z., and Mayer J.P. Melanocortin-4 receptor agonists for the treatment of obesity. Curr Top Med Chem 7 (2007) 1121-1130
24. Fong T.M., Mao C., MacNeil T., Kalyani R., Smith T., Weinberg D., Tota M.R., and Van der Ploeg L.H. ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors. Biochem Biophys Res Commun 237 (1997) 629-631
25. Ollmann M.M., Wilson B.D., Yang Y.K., Kerns J.A., Chen Y., Gantz I., and Barsh G.S. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278 (1997) 135-138
26. Mountjoy K.G., Robbins L.S., Mortrud M.T., and Cone R.D. The cloning of a family of genes that encode the melanocortin receptors. Science 257 (1992) 1248-1251
27. Gantz I., Konda Y., Tashiro T., Shimoto Y., Miwa H., Munzert G., Watson S.J., DelValle J., and Yamada T. Molecular cloning of a novel melanocortin receptor. J Biol Chem 268 (1993) 8246-8250
28. Gantz I., Miwa H., Konda Y., Shimoto Y., Tashiro T., Watson S.J., DelValle J., and Yamada T. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 268 (1993) 15174-15179
29. Gantz I., Shimoto Y., Konda Y., Miwa H., Dickinson C.J., and Yamada T. Molecular cloning, expression, and characterization of a fifth melanocortin receptor. Biochem Biophys Res Commun 200 (1994) 1214-1220
30. Yang Y.K., Fong T.M., Dickinson C.J., Mao C., Li J.Y., Tota M.R., Mosley R., Van Der Ploeg L.H., and Gantz I. Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry 39 (2000) 14900-14911
31. Haskell-Luevano C., Cone R.D., Monck E.K., and Wan Y.P. Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants. Biochemistry 40 (2001) 6164-6179
32. Pogozheva I.D., Chai B.X., Lomize A.L., Fong T.M., Weinberg D.H., Nargund R.P., Mulholland M.W., Gantz I., and Mosberg H.I. Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists. Biochemistry 44 (2005) 11329-11341
33. Nickolls S.A., Fleck B., Hoare S.R., and Maki R.A. Functional selectivity of melanocortin 4 receptor peptide and nonpeptide agonists: evidence for ligand-specific conformational states. J Pharmacol Exp Ther 313 (2005) 1281-1288
34. Farooqi I.S., Keogh J.M., Yeo G.S., Lank E.J., Cheetham T., and O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348 (2003) 1085-1095
35. Arasasingham P.N., Fotsch C., Ouyang X., Norman M.H., Kelly M.G., Stark K.L., Karbon B., Hale C., Baumgartner J.W., Zambrano M., Cheetham J., and Tamayo N.A. Structure-activity relationship of (1-aryl-2-piperazinylethyl)piperazines: antagonists for the AGRP/melanocortin receptor binding. J Med Chem 46 (2003) 9-11
36. Chen C., Pontillo J., Fleck B.A., Gao Y., Wen J., Tran J.A., Tucci F.C., Marinkovic D., Foster A.C., and Saunders J. 4-{(2R)-[3-Aminopropionylamido]-3-(2,4-dichlorophenyl)propionyl}-1-{2-[(2-thienyl)ethylaminomethyl]phenyl}piperazine as a potent and selective melanocortin-4 receptor antagonist-design, synthesis, and characterization. J Med Chem 47 (2004) 6821-6830
37. Ye Z., Guo L., Barakat K.J., Pollard P.G., Palucki B.L., Sebhat I.K., Bakshi R.K., Tang R., Kalyani R.N., Vongs A., Chen A.S., Chen H.Y., Rosenblum C.I., MacNeil T., Weinberg D.H., Peng Q., Tamvakopoulos C., Miller R.R., Stearns R.A., Cashen D.E., et al. Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]- 1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicycl o[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist. Bioorg Med Chem Lett 15 (2005) 3501-3505
38. Palucki B.L., Park M.K., Nargund R.P., Tang R., MacNeil T., Weinberg D.H., Vongs A., Rosenblum C.I., Doss G.A., Miller R.R., Stearns R.A., Peng Q., Tamvakopoulos C., Van der Ploeg L.H., and Patchett A.A. 2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists. Bioorg Med Chem Lett 15 (2005) 1993-1996
39. Palucki B.L., Park M.K., Nargund R.P., Ye Z., Sebhat I.K., Pollard P.G., Kalyani R.N., Tang R., Macneil T., Weinberg D.H., Vongs A., Rosenblum C.I., Doss G.A., Miller R.R., Stearns R.A., Peng Q., Tamvakopoulos C., McGowan E., Martin W.J., Metzger J.M., et al. Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-pipe ridinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarbo xamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist. Bioorg Med Chem Lett 15 (2005) 171-175
40. Fotsch C., Han N., Arasasingham P., Bo Y., Carmouche M., Chen N., Davis J., Goldberg M.H., Hale C., Hsieh F.Y., Kelly M.G., Liu Q., Norman M.H., Smith D.M., Stec M., Tamayo N., Xi N., Xu S., Bannon A.W., and Baumgartner J.W. Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides. Bioorg Med Chem Lett 15 (2005) 1623-1627
41. Fleck B.A., Chen C., Yang W., Huntley R., Markison S., Nickolls S.A., Foster A.C., and Hoare S.R. Molecular interactions of nonpeptide agonists and antagonists with the melanocortin-4 receptor. Biochemistry 44 (2005) 14494-14508
42. Xi N., Hale C., Kelly M.G., Norman M.H., Stec M., Xu S., Baumgartner J.W., and Fotsch C. Synthesis of novel melanocortin 4 receptor agonists and antagonists containing a succinamide core. Bioorg Med Chem Lett 14 (2004) 377-381
43. Vos T.J., Caracoti A., Che J.L., Dai M., Farrer C.A., Forsyth N.E., Drabic S.V., Horlick R.A., Lamppu D., Yowe D.L., Balani S., Li P., Zeng H., Joseph I.B., Rodriguez L.E., Maguire M.P., Patane M.A., and Claiborne C.F. Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J Med Chem 47 (2004) 1602-1604
44. Sebhat I.K., Martin W.J., Ye Z., Barakat K., Mosley R.T., Johnston D.B., Bakshi R., Palucki B., Weinberg D.H., MacNeil T., Kalyani R.N., Tang R., Stearns R.A., Miller R.R., Tamvakopoulos C., Strack A.M., McGowan E., Cashen D.E., Drisko J.E., Hom G.J., et al. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J Med Chem 45 (2002) 4589-4593
45. Yang Y., Dickinson C., Haskell-Luevano C., and Gantz I. Molecular basis for the interaction of [Nle4,D-Phe7]melanocyte stimulating hormone with the human melanocortin-1 receptor. J Biol Chem 272 (1997) 23000-23010
46. Haskell-Luevano C., Sawyer T.K., Trumpp-Kallmeyer S., Bikker J.A., Humblet C., Gantz I., and Hruby V.J. Three-dimensional molecular models of the hMC1R melanocortin receptor: complexes with melanotropin peptide agonists. Drug Des Discov 14 (1996) 197-211
47. Baldwin J.M. The probable arrangement of the helices in G protein-coupled receptors. EMBO J 12 (1993) 1693-1703
48. Yang Y.K., Dickinson C.J., Zeng Q., Li J.Y., Thompson D.A., and Gantz I. Contribution of melanocortin receptor exoloops to Agouti-related protein binding. J Biol Chem 274 (1999) 14100-14106
49. Chen M., Cai M., Aprahamian C.J., Georgeson K.E., Hruby V., Harmon C.M., and Yang Y. Contribution of the conserved amino acids of the melanocortin-4 receptor in [corrected] [Nle4,D-Phe7]-alpha-melanocyte-stimulating [corrected] hormone binding and signaling. J Biol Chem 282 (2007) 21712-21719
50. DeBlasi A., O'Reilly K., and Motulsky H.J. Calculating receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol Sci 10 (1989) 227-229
51. Yang Y.K., Ollmann M.M., Wilson B.D., Dickinson C., Yamada T., Barsh G.S., and Gantz I. Effects of recombinant agouti-signaling protein on melanocortin action. Mol Endocrinol 11 (1997) 274-280
52. Conrad D.M., Hanniman E.A., Watson C.L., Mader J.S., and Hoskin D.W. Ryanodine receptor signaling is required for anti-CD3-induced T cell proliferation, interleukin-2 synthesis, and interleukin-2 receptor signaling. J Cell Biochem 92 (2004) 387-399
53. Schioth H.B., Chhajlani V., Muceniece R., Klusa V., and Wikberg J.E. Major pharmacological distinction of the ACTH receptor from other melanocortin receptors. Life Sci 59 (1996) 797-801
54. Chen M., Aprahamian C.J., Kesterson R.A., Harmon C.M., and Yang Y. Molecular identification of the human melanocortin-2 receptor responsible for ligand binding and signaling. Biochemistry 46 (2007) 11389-11397
55. Van der Ploeg L.H., Martin W.J., Howard A.D., Nargund R.P., Austin C.P., Guan X., Drisko J., Cashen D., Sebhat I., Patchett A.A., Figueroa D.J., DiLella A.G., Connolly B.M., Weinberg D.H., Tan C.P., Palyha O.C., Pong S.S., MacNeil T., Rosenblum C., Vongs A., et al. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci U S A 99 (2002) 11381-11386
56. Martin W.J., McGowan E., Cashen D.E., Gantert L.T., Drisko J.E., Hom G.J., Nargund R., Sebhat I., Howard A.D., Van der Ploeg L.H., and MacIntyre D.E. Activation of melanocortin MC(4) receptors increases erectile activity in rats ex copula. Eur J Pharmacol 454 (2002) 71-79
57. Chen M., Aprahamian C.J., Celik A., Georgeson K.E., Garvey W.T., Harmon C.M., and Yang Y. Molecular characterization of human melanocortin-3 receptor ligand-receptor interaction. Biochemistry 45 (2006) 1128-1137
58. Hogan K., Peluso S., Gould S., Parsons I., Ryan D., Wu L., and Visiers I. Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for receptor activation. J Med Chem 49 (2006) 911-922
59. Kristiansen K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther 103 (2004) 21-80
60. Yang Y., Chen M., Lai Y., Gantz I., Georgeson K.E., and Harmon C.M. Molecular determinants of human melanocortin-4 receptor responsible for antagonist SHU9119 selective activity. J Biol Chem 277 (2002) 20328-20335
61. Mutulis F., Yahorava S., Mutule I., Yahorau A., Liepinsh E., Kopantshuk S., Veiksina S., Tars K., Belyakov S., Mishnev A., Rinken A., and Wikberg J.E. New substituted piperazines as ligands for melanocortin receptors. Correlation to the X-ray structure of "THIQ". J Med Chem 47 (2004) 4613-4626
62. Perlman S., Costa-Neto C.M., Miyakawa A.A., Schambye H.T., Hjorth S.A., Paiva A.C., Rivero R.A., Greenlee W.J., and Schwartz T.W. Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations. Mol Pharmacol 51 (1997) 301-311